Global Skin Cancer Diagnosis and Therapeutics Market Valued at $14.0 Billion in 2025, Expanding at 6.1% CAGR

Global skin cancer diagnosis and therapeutics market was valued at $14.0 billion in 2025 and is growing at a CAGR of 6.1% during the forecast period (2026-2035). Regulatory approval of the first cell therapy for solid tumors marks a milestone in oncology, broadening treatment avenues from solely hematological cancers to include advanced skin cancers. This development endorses tumor-infiltrating lymphocyte (TIL) approaches, thereby encouraging greater clinical implementation and facilitating market growth through the expansion of treatment pipelines. For instance, in February 2024, FDA approved lifileucel, the first cancer cell therapy for solid tumors, specifically for advanced melanoma. This one-time T-cell therapy, manufactured by Iovance Biotherapeutics and branded as Amtagvi, is indicated for adults with unresectable or metastatic melanoma who have previously received PD-1 inhibitors and, if BRAF V600-positive, a BRAF inhibitor with or without a MEK inhibitor.

Browse the full report description of “Skin Cancer Diagnosis and Therapeutics Market Size, Share & Trends Analysis Report by Cancer Type (Melanoma, and Non-Melanoma), by Diagnosis Type (Dermatoscopy, Biopsy, Imaging Techniques, Molecular Diagnostics, and Blood Tests), by Therapeutic Type (Surgical Procedures, Radiation Therapy, Chemotherapy, Targeted Therapy, Immunotherapy, Photodynamic Therapy, Topical Treatments, and Others), and by End User (Hospitals, Specialty Dermatology Clinics, Cancer Treatment Centers, Ambulatory Surgical Centers, Diagnostic Laboratories, and Research & Academic Institutes) Forecast Period (2025-2035)” at https://www.omrglobal.com/industry-reports/skin-cancer-diagnosis-and-therapeutics-market

Leading Companies Advancing Innovation in Skin Cancer Diagnosis and Therapeutics

Key players in the global skin cancer diagnosis and therapeutics market, including Amgen Inc., Bristol-Myers Squibb Co., F. Hoffmann-La Roche Ltd., Merck & Co., Inc., and Sun Pharmaceutical Industries Ltd.—are at the forefront of innovation across the care continuum. These companies are driving advancements in targeted therapies, immuno-oncology drugs, combination treatment regimens, and precision diagnostics, supported by ongoing investments in biomarker research, clinical trials, and early detection technologies. Their efforts are improving treatment efficacy, patient outcomes, and survival rates, while shaping the future landscape of skin cancer management globally.

• In February 2024, FDA has approved Amtagvi (lifileucel), the first cellular therapy for adult patients with unresectable or metastatic melanoma, which cannot be surgically removed and has not responded to previous treatments like PD-1 inhibitors or BRAF inhibitors. Melanoma, while only 1% of skin cancers, leads to a disproportionate number of cancer deaths and can metastasize if not treated early. Treatments often include immunotherapy targeting PD-1 and BRAF gene therapies, highlighting a significant medical need for patients whose melanoma has progressed despite these options.
• In January 2024, FDA approved DermaSensor, the first AI-powered diagnostic tool for skin cancer, enabling noninvasive and quantitative identification of melanoma, basal cell carcinoma, and squamous cell carcinoma at the point of testing. Utilizing AI-driven spectroscopy, DermaSensor analyzes cellular and subcellular characteristics of skin lesions through a wireless, handheld device with an FDA-cleared algorithm. The approval is based on the DERM-SUCCESS study led by the Mayo Clinic, which involved over 1000 patients and demonstrated a 96% sensitivity for all 224 types of skin cancer. Additionally, the device showed a 97% likelihood of benign results for negative tests. A clinical utility study revealed that DermaSensor reduced the number of missed cancers by half (from 18% to 9%) among 108 physicians, while also increasing the referral rates for skin cancer treatments (from 81% to 94%).

Market Coverage

• The market number available for – 2025-2035
• Base year- 2025
• Forecast period- 2026-2035
• Segment Covered-
  • By Cancer Type
  • By Diagnosis Type
  • By Therapeutic Type
  • By End User
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
• Competitive Landscape - Amgen Inc., Bristol-Myers Squibb Co., F. Hoffmann-La Roche Ltd, Merck & Co., Inc., Sun Pharmaceutical Industries Ltd., among others.

Key questions addressed by the report.

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Skin Cancer Diagnosis and Therapeutics Market Report Segment

By Cancer Type

• Melanoma
• Non-Melanoma

By Application

• Dermatoscopy
• Biopsy
• Imaging Techniques
• Molecular Diagnostics
• Blood Tests

By Therapeutic Type

• Surgical Procedures
• Radiation Therapy
• Chemotherapy
• Targeted Therapy
• Immunotherapy
• Photodynamic Therapy
• Topical Treatments
• Others (Laser Therapy, and Vaccine Therapy)

By End User

• Hospitals
• Specialty Dermatology Clinics
• Cancer Treatment Centers
• Ambulatory Surgical Centers
• Diagnostic Laboratories
• Research & Academic Institutes

Global Skin Cancer Diagnosis and Therapeutics Market Report Segment by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Russia
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Australia and New Zealand
• ASEAN Economies
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/skin-cancer-diagnosis-and-therapeutics-market